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In B-cell precursor acute lymphoblastic leukemia, the initial leukemiccells share the same antigen receptor gene rearrangements. However,due to ongoing rearrangement processes, leukemic cells with different
gene rearrangement patterns can develop, resulting in subclone forma-
tion. We studied leukemic subclones and their distribution in the bone
marrow and peripheral blood at diagnosis. Antigen receptor gene
rearrangements (IGH, IGK, TRG, TRD, TRB) were analyzed by next-
generation sequencing in seven paired bone marrow samples and five
paired bone marrow-peripheral blood samples. Background-thresholds
were defined, which enabled identification of leukemic gene rearrange-
ments down to very low levels. Paired bone marrow analysis showed
oligoclonality in all 7 patients and up to 34 leukemic clones per patient.
Additional analysis of evolutionary-related IGH gene rearrangements
revealed up to 171 leukemic clones per patient. Interestingly, overall 86%
of all leukemic gene rearrangements, including small subclones, were
present in both bone marrow samples (range per patient: 72-100%).
Paired bone marrow-peripheral blood analysis showed that 83% of all
leukemic gene rearrangements in bone marrow were also found in
peripheral blood (range per patient: 81-100%). Remarkably, in the paired
bone marrow samples and paired bone marrow-peripheral blood sam-
ples the vast majority of leukemic gene rearrangements had a similar fre-
quency (<5-fold frequency difference) (96% and 96% of leukemic
rearrangements, respectively). Together, these results indicate that B-cell
precursor acute lymphoblastic leukemia is generally highly oligoclonal.
Nevertheless, the vast majority of leukemic clones, even the minor anti-
gen receptor-defined subclones, are homogeneously distributed through-
out the bone marrow and peripheral blood compartment. 
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ABSTRACT
Introduction
During B-cell and T-cell differentiation, genes that encode the B-cell receptor
(Immunoglobulin; IG) and the T-cell receptor (TR) are rearranged, respectively. This
process of IG and TR gene rearrangement includes the assembly of Variable (V),
Diversity (D) and Joining (J) gene segments and the random insertion and deletion
of nucleotides between these gene segments,1,2 resulting in unique V-(D)-J junctions.
In normal B cells and T cells, productive V-(D)-J exons encode the antigen-binding
domains of the IG and TR molecules. The large diversity of V-(D)-J junctions con-
tributes significantly to the large diversity of IG and TR molecules, thereby provid-
ing the B and T lymphocytes with a wide variety of antigen specificities.
B-cell precursor acute lymphoblastic leukemia (BCP-ALL) arises from a malignant-
ly transformed B-cell precursor (BCP).3 Therefore, BCP-ALL cells contain IG gene
rearrangements in the vast majority of cases.4 In addition,
most BCP-ALL cells also harbor certain TR gene rearrange-
ments, which are uncommon in normal BCPs.5-7 Since
BCP-ALL is thought to arise from a single cell, a BCP-ALL
population is expected to be monoclonal with regard to
IG/TR gene rearrangements, i.e. to consist of cells which
all share the same IG/TR gene rearrangements. However,
continuing rearrangement processes and V-segment
replacements that occur in normal BCP cells can also occur
during the development of BCP-ALL.8-10 As a result, a BCP-
ALL population can be oligoclonal, i.e. can contain sub-
clones with IG/TR gene rearrangements that deviate from
those in the initial leukemic cell. 
Several previous studies had analyzed IG/TR gene
rearrangements in BCP-ALL diagnosis samples by using
PCR-based methods in combination with Southern blot
(SB), which allowed identification of clonal IG/TR gene
rearrangements down to the level of 1-5%.11,12 In these
studies, oligoclonality was detected in 40% of patients
when analyzing the IGH and TRD loci and in 10-20% of
patients when analyzing the IGK and TRB loci.11-13 With
regard to complete IGH gene rearrangements, a maximum
of 9 clonal rearrangements could be found per patient.14
More recently, IGH gene rearrangements in BCP-ALL at
diagnosis were analyzed with highly sensitive next-gener-
ation sequencing (NGS), which showed that many more
clonal IGH gene rearrangements (up to 4024) can be pres-
ent in a single patient.15 However, in NGS studies of IG/TR
gene rearrangements in BCP-ALL patients, it is difficult to
discriminate leukemic rearrangements at low-frequency
levels from the background of normal lymphocyte-
derived rearrangements and from technical artifacts.
Furthermore, NGS-based analysis of gene rearrangements
other than complete IGH gene rearrangements has, to the
best of our knowledge, so far not been performed in
patients with BCP-ALL. Therefore, the degree of oligo-
clonality in BCP-ALL patients, especially at low-frequency
level, remains unclear.
BCP-ALL subclones may develop at different locations
in the body, after which they may disseminate throughout
the bone marrow (BM) and peripheral blood (PB) compart-
ment. Whereas minimal residual disease (MRD) levels
were shown to be comparable between paired BM sam-
ples during follow up,16 limited data are available on the
distribution of BCP-ALL clones at the time of diagnosis.
Our early SB study on IG/TR gene rearrangements in
paired BM-PB samples at diagnosis reported that in 5 out
of 10 oligoclonal patients, subclonal IGH gene rearrange-
ments were found in the BM sample, but not in the corre-
sponding PB sample.17 However, the relative frequency of
these subclonal IGH gene rearrangements in PB might
have been too low to be detected with SB. Therefore, it is
still unknown to what extent BCP-ALL clones are distrib-
uted throughout the BM and PB compartments.  
Here, we studied the distribution of leukemic clones in
BCP-ALL patients by performing NGS of IG/TR gene
rearrangements on paired BM-BM samples as well as
paired BM-PB samples. 
Methods
Patient and control samples
Bone marrow and PB samples from a total of 12 children with
newly diagnosed BCP-ALL were collected (Online Supplementary
Table S1). These samples included seven left BM-right BM pairs,
i.e. BM from the left and right pelvic bone of the same patient, and
five BM-PB pairs, all taken at initial diagnosis. One BM sample
from a healthy child (residual material from a donor for allogeneic
BM transplantation), two BM samples from BCP-ALL patients at
one year after end of therapy, and five regenerating BM samples
from T-ALL patients at day 79 and month 5 during therapy were
collected to be used as control samples. All control samples were
MRD negative according to allele-specific oligonucleotide PCR
assays, as described previously.4,18 All samples were obtained
according to the guidelines of the local Medical Ethics
Committees (MEC 2004-203 and MEC 2012-287) and in line with
the Declaration of Helsinki Protocol.
Next-generation sequencing by the Adaptive
Biotechnologies method
Genomic DNA was isolated from BM and PB mononuclear cells
(MNCs) by the QIAamp DNA Mini Kit (Qiagen, Hilden,
Germany). A detailed description of the NGS-based immunose-
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Table 1. Number and distribution of leukemic clones at B-cell precursor acute lymphoblastic leukemia (BCP-ALL) diagnosis in paired bone marrow
(BM) samples.a
ID_15760 ID_15773 ID_15803 ID_16079 ID_16261 ID_16278 ID_16300 Total
n clones n clones n clones n clones  n clones n clones n clones n clones 
paired/total paired/total paired/total paired/total paired/total paired/total paired/total paired/total
Vh-Jh 2/2 (100%) 4/4 (100%) 30/34 (88%) 11/14 (79%) 6/7 (86%) 19/25 (76%) 2/2 (100%) 74/88 (84%)
Dh-Jh - - 4/5 (80%) - - - - 4/5 (80%)
V κ-Jκ - - 0/0 (NA) - 2/2 (100%) 5/5 (100%) 1/1 (100%) 8/8 (100%)
Vκ-KDE 1/1 (100%) 1/1 (100%) 1/1 (100%) 1/1 (100%) - 2/2 (100%) 2/2 (100%) 8/8 (100%)
IntronRSS-KDE - - - - 3/3 (100%) - - 3/3 (100%)
V γ-Jγ 2/2 (100%) 3/3 (100%) 0/0 (NA) 21/22 (96%) 5/5 (100%) 19/20 (95%) 5/5 (100%) 55/57 (96%)
Vδ-Dδ 1/1 (100%) - 12/26 (46%) 9/9 (100%) - 8/9 (89%) - 30/45(67%)
Dδ-Dδ - - - 6/7 (86%) - - 2/2 (100%) 8/9 (89%)
Vβ-Jβ - 3/3 (100%) 1/1 (100%) 4/4 (100%) 1/1 (100%) - 2/2 (100%) 11/11 (100%)
Total 6/6 11/11 48/67 52/57 17/18 (94%) 53/61 14/14 201/234 (86%)
(100%) (100%) (72%) (91%) (87%) (100%)
aThe number of leukemic Vh-DJh, Dh-Jh, Vκ-Jκ, Vκ-KDE, intronRSS-KDE, Vγ-Jγ , Vδ-Dδ, Dδ-Dδ and Vβ-Jβ rearrangements and the percentage of these leukemic rearrangements that
was homogeneously distributed (i.e. found in both BM samples), in BCP-ALL patients at diagnosis. n: number; Intr-KDE: intronRSS-KDE. -: total RC <1000; NA: not applicable.
quencing method has been published elsewhere.19 Briefly, a DNA
quantity of 420-480 ng, corresponding to 70,000-80,000 MNCs,
was used for the amplification of complete IGH gene rearrange-
ments (Vh-DJh; three separate PCRs) and a DNA quantity of 120-
180 ng, corresponding to 20,000-30,000 MNCs, was used for the
amplification of incomplete IGH gene rearrangements (Dh-Jh),
IGK gene rearrangements (Vκ-Jκ, Vκ-KDE, intronRSS-KDE), TRG
gene rearrangements (Vγ-Jγ), TRD gene rearrangements (Vδ-Dδ,
Dδ-Dδ) and TRB gene rearrangements (Vβ-Jβ) (all single PCRs).
These rearrangements were amplified in a first PCR reaction of 25
cycles, using locus-specific primer sets.20 Next, 1:100 of these PCR
products was further amplified in a second PCR reaction of 14
cycles, using universal primers complementary to the adaptors
that were linked to the locus-specific primers with sample-identi-
fiers. The final PCR products were sequenced using the Illumina
HiSEQ platform. Low-quality reads were filtered out and
sequences with a single read were excluded.19 For each sequence,
the absolute read count, i.e. the read count corrected for PCR
amplification by the spike-in method, was calculated (Online
Supplementary Methods). Also the frequency for each sequence was
determined. Importantly, the frequency represents a fraction of
the rearranged genes of the involved locus, rather than a fraction
of all, including germline, IG and TR genes, as is the case in SB and
PCR-based IG/TR gene rearrangement analysis (Online
Supplementary Methods).
NGS clonal variant comparison pipeline and data
analysis
We developed a new analysis tool (PRISCA: PRecISe Clonal
Analysis) in Galaxy21 to compare sequences from paired and trip-
licate samples (Online Supplementary Methods). The graphical out-
put from this tool was used for further data analysis. The IG/TR
gene rearrangements at diagnosis were subsequently analyzed
according to the criteria described in the Online Supplementary
Methods. In line with previous reports,19,22-24 an index clone was
arbitrarily defined as a clonal IG/TR gene rearrangement  with a
frequency >5%. 
Results
Normal and regenerating BM samples define 
thresholds for the exclusion of normal 
lymphocyte-derived IG/TR gene rearrangements 
For in-depth analysis of IG/TR gene rearrangements in
BCP-ALL patients, it is necessary to discriminate the
IG/TR gene rearrangements derived from leukemic clones
Homogeneous distribution of ALL subclones
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Figure 1. Read counts (RC) of Vh-DJh rearrange-
ments in bone marrow (BM) from a healthy
child, a T- cell acute lymphoblastic leukemia (T-
ALL) patient at a therapy interval (regenerating
BM) and a B-cell precursor (BCP)-acute lym-
phoblastic leukemia (ALL) patient at one year
after end of therapy (representative examples
of all non-leukemic BM samples; total n=8). Vh-
DJh with a read count of <1 (caused by amplifi-
cation-correction) were displayed as rearrange-
ments with a read count of 1. Black line indi-
cates the established threshold for Vh-DJh
rearrangements. Regenerating BM showed
structurally lower numbers of unique Vh-DJh
rearrangements compared to healthy control
BM and BM one year after end of therapy. This
was also true for Vκ-Jκ, Vκ-KDE and intronRSS-
KDE rearrangements, but not Dh-Jh rearrange-
ments (Online Supplementary Figure S1). This
was expected, since the B-cell population in
regenerating BM mainly consists of pre-B-I stage
cells.25,26
from the background that also contains IG/TR gene
rearrangements derived from normal B-cell and T-cell
clones. We therefore aimed to define read count thresh-
olds (RCTs) above which we can fairly assume normal
lymphocyte-derived IG/TR gene rearrangements to be
absent. To define these RCTs, we determined the maxi-
mum of the absolute read counts of normal lymphocyte-
derived IG/TR gene rearrangements detected in eight non-
leukemic BM samples, i.e. a normal BM sample from a
healthy child, two normal BM samples from BCP-ALL
patients one year after end of therapy, and five regenerat-
ing BM samples from T-ALL patients during therapy inter-
vals. Importantly, regenerating BM samples did not con-
tain residual leukemic IG/TR gene rearrangements (as
determined by the absence of leukemic IG/TR gene
rearrangements which were found by NGS in the corre-
sponding diagnosis sample) (data not shown). We particular-
ly included regenerating BM samples (and only limited
healthy BM samples) as controls since we expected the
highest background of IG/TR rearrangements in such
samples with increased numbers of early B-cell precursors.
Analysis of complete IGH gene rearrangements showed
that the maximum read count of complete IGH gene
rearrangements in the non-leukemic BM samples was 26
(Figure 1). The IGH Vh-DJh RCT was therefore set at 30
reads. The same strategy was applied to the other types of
IG/TR gene rearrangements, resulting in an RCT of 30
reads for Dh-Jh rearrangements, 70 reads for Vκ-Jκ
rearrangements, 40 reads for Vκ-KDE rearrangements, 170
reads for intronRSS-KDE rearrangements, 50 reads for 
Vγ-Jγ rearrangements, 20 reads for Vδ-Dδ rearrangements,
30 reads for Dδ-Dδ rearrangements, and 30 reads for Vγ-Jβ
rearrangements (Online Supplementary Figure S1). The rela-
tively high maximum read count of intronRSS-KDE
rearrangements was probably due to the limited junction-
al variability of intronRSS-KDE rearrangements.
Importantly, these RCTs are dependent on DNA input and
are therefore not universal, but are specific for our data. 
Samples run in triplicate show that our thresholds also
exclude IG/TR gene rearrangements derived from tech-
nical artifacts
We aimed to evaluate whether IG/TR gene rearrange-
ments with a read count above the RCTs were truly clon-
al, i.e. were derived from leukemic clones and not from
technical artifacts (non-clonal rearrangements whose read
counts were insufficiently corrected after PCR amplifica-
tion). We therefore prepared three independent libraries of
the same sample and performed three independent NGS-
runs, based on the fair assumption that IG/TR gene
rearrangements can be regarded as clonal if present in all
three samples or if present in two of the three samples
(since small clones can coincidently be absent in a sam-
pling volume). Analysis of complete IGH gene rearrange-
ments in a BM sample at diagnosis showed that all com-
plete IGH gene rearrangements with a read count above
the previously defined RCT, and thus considered to be
derived from leukemic clones, were present in all three
P. M.J. Theunissen et al.
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Figure 2. Read counts of Vh-DJh rearrange-
ments in bone marrow (BM) replicates from
a B-cell precursor (BCP)-acute lymphoblas-
tic leukemia (ALL) patient at diagnosis.
This BM was sequenced in triplicate, result-
ing in IGH gene rearrangements that were
found in one, in two or in all three replicates.
Vh-DJh rearrangements with a read count of
<1 (caused by amplification-correction) were
displayed as rearrangements with a read
count of 1. Black line indicates the previous-
ly defined threshold for Vh-DJh rearrange-
ments (30 reads). 
replicates, indicating that these were not technical arte-
facts (Figure 2). Analysis of the other IG/TR gene
rearrangement types in this diagnosis sample showed the
same (Online Supplementary Figure S2). Thus, by using
these RCTs, we ensured that the included rearrangements
(above the RCT) were very likely to be derived from
leukemic clones (as opposed to normal lymphocytes or
technical artefacts), thereby accepting that leukemic
rearrangements with a read count below the RCT will be
ignored. Analysis of IG/TR gene rearrangements in a
regenerating BM sample of a T-ALL patient showed, as
expected, that none of the rearrangements had a read
count above the RCT. Nevertheless, part of the IG/TR
gene rearrangements with a read count below the RCT
were present in two or three of the replicates, and could
thus be derived from normal B-cell or T-cell clones (Online
Supplementary Figure S3).
Paired BM samples show homogeneous distribution in
BCP-ALL, also for small subclones
Next, we aimed to analyze the number and particularly
the tissue distribution of clones in BCP-ALL patients.
Therefore, we performed NGS of IG/TR gene rearrange-
ments in paired BM samples (from the left and the right
pelvic bone) from newly diagnosed BCP-ALL patients
(n=7). By applying the previously described thresholds
(now expressed as frequency) and analysis criteria (Online
Supplementary Methods) to complete IGH rearrangements,
oligoclonality was detected in 6 out of 7 BCP-ALL patients
(Figure 3). The number of index clones (frequency of >5%)
ranged from 1 to 5 (median: 1), whereas the total number
of (sub)clones ranged from 2 to 34. With regard to distri-
bution of the clones, 84% (74 out of 88) of all leukemic
Vh-DJh rearrangements were paired (i.e. present in both
BM samples), ranging from 76% to 100% per patient
(Figure 3). Importantly, 61 out of the 74 (82%) paired
leukemic Vh-DJh rearrangements had a comparable fre-
quency (<5-fold difference) in the two BM samples.
Within the 13 paired leukemic Vh-DJh index clones, all
Vh-DJh rearrangements had a comparable frequency in
the two BM samples. The leukemic Vh-DJh rearrange-
ments which were present in only one of the two samples
all had a very low frequency (below 0.2%) and often
shared a common Dh-Jh stem with a paired leukemic Vh-
DJh rearrangement (see below). Analysis of the other types
of IG/TR gene rearrangements also showed that the vast
majority of the leukemic rearrangements were paired: 4
out of 5 (80%) Dh-Jh rearrangements, 8 out of 8 (100%)
Vκ-Jκ rearrangements, 8 out of 8 (100%) Vκ-KDE
rearrangements, 3 out of 3 (100%) intronRSS-KDE
rearrangements, 55 out of 57 (96%) Vγ-Jγ rearrangements,
30 out of 45 (67%) Vδ-Dδ rearrangements, 8 out of 9
(89%) Dδ-Dδ rearrangements, and 11 out of 11 (100%)
Vβ-Jβ rearrangements (Online Supplementary Figure S4).
Within all paired leukemic IG/TR gene rearrangements,
171 out of all 199 (86%) showed a comparable frequency
in the two BM samples. The overall results per patient are
summarized in Table 1. 
Analysis of leukemic Dh-Jh stems at very low frequency
levels suggests even higher numbers of homogeneously
distributed subclones 
We subsequently aimed to estimate the number of
leukemic IG/TR gene rearrangements that were present at
very low frequencies and that were, based on the back-
ground-threshold, excluded from previous analyses.
Therefore, we visualized all paired complete IGH gene
rearrangements, irrespective of their frequency (i.e. also
with a frequency below the threshold). Only paired IGH
gene rearrangements (i.e. present in both BM samples)
were visualized in order to exclude potential technical
artifacts. The resulting graph showed that, besides the
previously detected paired IGH gene rearrangements,
many more paired IGH gene rearrangements were present
below the threshold (Figure 4). However, a paired IGH
gene rearrangement below the threshold can either be
Homogeneous distribution of ALL subclones
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Figure 3. Frequencies of leukemic Vh-DJh rearrangements in paired bone marrow (BM) samples [left (L) and right (R) pelvic bone] from B-cell precursor (BCP)-
acute lymphoblastic leukemia (ALL) patients at diagnosis. For each leukemic Vh-DJh rearrangement, the presence in both BM samples (L+R) or in only one of the
two BM samples (L or R) is indicated. The background area, which also contains Vh-DJh rearrangements derived from normal B-cell clones, is indicated for each
sample (gray). *Vh-DJh rearrangement sharing a common Dh-Jh stem with a paired leukemic Vh-DJh rearrangement. 
derived from a leukemic clone or derived from a normal
mature B-cell clone which had been distributed through-
out the BM compartment. To discriminate, at sub-thresh-
old level, leukemia-derived IGH gene rearrangements
from normal B-cell-derived IGH gene rearrangements, we
searched for common Dh-Jh stems. An IGH gene
rearrangement below the threshold that shared a common
Dh-Jh stem with a leukemic IGH gene rearrangement
above the threshold was also considered leukemic (since
both were derived from the same ancestral clone). This
analysis showed that, on top of the leukemic IGH gene
rearrangements found in the previous analyses (above the
threshold), even more leukemic IGH gene rearrangements
are present at very low frequency levels (below the thresh-
old) (summarized in Figure 5). The exact number of
leukemic IGH gene rearrangement per patient remains
unknown, since the origin (leukemia- or mature B-cell-
derived) of the IGH gene rearrangements with a frequency
below the threshold and without a common Dh-Jh stem
could not be determined. Of note, the IGH gene
rearrangements with a common Dh-Jh stem also often
had a common V-D junction, indicating that V to D-J join-
ing as well as Vh-replacement had taken place.
Paired BM-PB samples confirm the homogeneous 
distribution of BCP-ALL clones via PB 
The above data indicate that BCP-ALL clones are dis-
tributed homogeneously over the BM compartment,
implying that migration via PB is required. Therefore, we
investigated whether leukemia-derived IG/TR gene
rearrangements detected in BM can also be found in PB.
To do so, we performed NGS of IG/TR gene rearrange-
ments in paired BM-PB samples from 5 newly diagnosed
BCP-ALL patients. Leukemic IG/TR gene rearrangements
found in the BM sample (i.e. with a frequency above the
previously established thresholds) were searched in the
corresponding PB sample and classified as ‘paired’ when
also present in the PB sample. Analysis of complete IGH
gene rearrangements showed that 98% (43 out of 44) of all
leukemic Vh-DJh rearrangements were paired (Figure 6).
Forty-two of the 43 (98%) paired leukemic Vh-DJh
rearrangements had a comparable frequency (<5-fold dif-
ference) in the two corresponding samples. The only
leukemic Vh-DJh rearrangement present in the BM sample
but not in the PB sample, had a frequency of 0.04% and
shared a common Dh-Jh stem with a paired leukemic Vh-
DJh rearrangement. Analysis of the other IG and TR gene
rearrangement types also showed that the majority of the
leukemic rearrangements were paired: 30 out of 32 (94%)
Dh-Jh rearrangements, 2 out of 2 (100%) Vκ-Jκ rearrange-
ments, 1 out of 1 (100%) Vκ-KDE rearrangements, 9 out
of 9 (100%) Vγ-Jγ rearrangements, 320 out of 403 (79%)
Vδ-Dδ rearrangements, 17 out of 17 (100%) Dδ-Dδ
rearrangements, and 4 out of 4 (100%)  Vβ-Jβ rearrange-
ments (no clonal intronRSS-KDE rearrangements were
found) (Online Supplementary Figure S5). Within all paired
leukemic IG/TR gene rearrangements, 411 out of all 426
(96%) showed a comparable frequency between the BM
and the corresponding PB sample.
Discussion
To study the number of clones and their distribution in
patients with BCP-ALL, we performed NGS of IG/TR
gene rearrangements in paired BM-BM and BM-PB sam-
ples at diagnosis. First, we aimed to carefully define back-
ground RCTs, which exclude normal lymphocyte-derived
IG/TR gene rearrangements when using an identical
amount of DNA per sample. Therefore, we determined
the maximum read count of these normal lymphocyte-
derived IG/TR gene rearrangements in non-leukemic BM,
i.e. healthy control BM, regenerating BM, and BM one
year after end of therapy. Second, by analyzing BCP-ALL
samples at diagnosis in triplicate, we confirmed that all
IG/TR gene rearrangements with a read count above the
pre-set RCT represented clonal IG/TR gene rearrange-
ments, and not technical artifacts.  Of note, RCTs could
not exclude IG/TR gene rearrangements derived from nor-
mal lymphocyte expansions directed against leukemic
cells, since these expansions were not present in the stud-
ied follow-up samples (or in the healthy control BM sam-
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Figure 4. Frequencies of Vh-DJh rearrangements in paired bone marrow (BM) samples [left (L) and right (R) pelvic bone] from B-cell precursor (BCP)-acute lym-
phoblastic leukemia (ALL) patients at diagnosis. All paired Vh-DJh rearrangements are shown, i.e. with a frequency above as well as below the threshold. Background
area of each sample is indicated in gray.   
ple). However, since many Vh-DJh rearrangements shared
a common stem with an index clone and since, besides
clonal TR gene rearrangements, also clonal IG gene
rearrangements were observed (whereas reactive expan-
sions against leukemic cells would be mainly of T-cell ori-
gin), it is likely that most IG/TR gene rearrangements with
read counts above the RCTs are of leukemic origin.
Analysis of IG/TR gene rearrangements in paired BM-
BM diagnosis samples showed that all 7 patients were
oligoclonal. Remarkably high numbers of leukemic Vh-
DJh, Vγ-Jγ and Vδ-Dδ rearrangements per patient could be
detected (e.g. up to 34 leukemic Vh-DJh rearrangements).
Even higher numbers of leukemic rearrangements per
patient were detected when common Dh-Jh stem (junc-
tion sequence) analysis was used to also include Vh-DJh
rearrangements below the background threshold (up to
171 leukemic Vh-DJh rearrangements). Previous studies
that had used SB to analyze IG/TR gene rearrangements
reported that only 40% of the ALL-patients were oligo-
clonal, with maximally 9 leukemic rearrangements per
patient.11,14 The discrepancies between these previous
findings and our current results can be explained by the
difference in sensitivity of the applied methods. A more
recent study that used NGS to analyze IGH gene
rearrangements, showed, in line with our results, that far
more IGH gene rearrangements per patient can be found
when analysis down to very low frequency levels is
allowed.15 However, in contrast with our results, this
study also reported on a few patients (4 out of the 51 stud-
ied patients) in which more than 1000 leukemic IGH gene
rearrangements were found. Patients with such exception-
ally high numbers of IGH gene rearrangements were not
present in our study, which is probably related to the
lower number of patients analyzed. In any case, we
showed that the number of leukemic IG/TR gene
rearrangements per BCP-ALL patient is considerably high-
er than previously observed.
IG/TR gene rearrangements are used as PCR targets for
MRD detection.27-31 Insight into subclone formation and
distribution of these subclones might improve selection of
MRD targets. Our current findings indicate that MRD tar-
gets have so far been selected from only a small part of the
total number of leukemic IG/TR gene rearrangements
present at diagnosis, i.e. from those that were sufficiently
large to be detected by PCR-based methods (generally
index clones, i.e. with a frequency >5%). Still, more than
90% of the relapsed cases had maintained the IG and TR
targets selected at diagnosis.30 Apparently, monitoring of
only the index clones might be sufficient to predict relapse
in most BCP-ALL patients. Furthermore, our observation
that the vast majority of leukemic clones could be detect-
ed both in BM and PB implies that also PB samples may
reliably be used for NGS-based selection of MRD targets.
By analyzing paired BM samples, we showed that the
vast majority of the leukemic rearrangements were pres-
ent in both BM samples and that their frequency was gen-
Homogeneous distribution of ALL subclones
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Figure 5. Schematic representation of the relations between Vh-DJh rearrangements, based on common Dh-Jh stems, in bone marrow (BM) samples from B-cell
precursor (BCP)-acute lymphoblastic leukemia (ALL) patients at diagnosis. The size of the circle represents the frequency of the Vh-DJh rearrangement. Blue or red
indicates a leukemic origin (blue: based on frequency; red: based on a common Dh-Jh stem), whereas green indicates small clones of unknown origin (no leukemic
Dh-Jh stem).
erally similar in both samples. The few leukemic
rearrangements that were present in only one of the two
samples generally had a low frequency (<2%). Probably,
also these low-frequent clones were present in the whole
BM compartment, but were absent in one of the two sam-
ples based on statistical chance. By analyzing paired BM-
PB samples (from other patients), we showed that almost
all leukemic rearrangements that were present in BM,
were also present in PB, generally at a similar frequency.
As an exception to the above discussed results, relatively
many leukemic Vδ-Dδ rearrangements in patient 15803
(child with a TCF3-PBX1 translocation) and in patient
15507 (infant with an MLL-ENL translocation) were pres-
ent in only one of the paired BM samples (54% and 22%,
respectively). Since infants with a MLL-R translocation are
known to be highly oligoclonal,32,33 the specific genetic
aberrancies might be associated with the deviating results
on Vδ-Dδ rearrangements.34 It is important to note that we
analyzed diagnosis samples in which tumor percentages
were generally high, and that the situation during treat-
ment (with lower numbers of ALL cells) might be differ-
ent. Nevertheless, our previous study16 suggests that also
in an MRD setting the ALL clones are homogeneously dis-
tributed over the BM compartment.
Next-generation sequencing-based IG and TR gene
rearrangement analysis in paired BM-BM and BM-PB sam-
ples from newly diagnosed BCP-ALL patients has, to our
knowledge, not been performed previously. Our early SB
study on IG gene rearrangements in paired BM-PB sam-
ples of newly diagnosed BCP-ALL patients showed that a
relatively high number of leukemic IGH gene rearrange-
ments were detected in the BM sample, but not or in a
lower frequency in the corresponding PB sample,17 which
seems to be in contrast with our current results. However,
this discrepancy is probably due to technical differences
between Southern blot and NGS analytical methods (see
Methods section). 
Together, our paired BM-BM and paired BM-PB NGS
analyses showed that almost all leukemic IG/TR gene
rearrangements are present in comparable frequencies in the
BM and PB compartment. We did not study leukemic IG/TR
gene rearrangements in tissues other than BM or PB.
However, it might be speculated that extramedullary dis-
semination is different from distribution within the BM and
PB compartment, since only clones with specific character-
istics (e.g. homing receptors) are able to migrate to
extramedullary sites.35 Furthermore, it should be noted that
we defined subclones based on IG/TR gene rearrangements.
It may well be that subclones with different somatic muta-
tions, related to leukemogenesis and prone to positive selec-
tion, are distributed in a less homogeneous way. Exome
sequencing of paired BM samples may answer this question.
In conclusion, by using NGS data in combination with
carefully defined thresholds, we were able to study
leukemic IG/TR gene rearrangements down to a low level
(0.01-0.1%), without the interference of background
rearrangements. By studying paired BM-BM and paired
BM-PB samples, we showed that the relative quantity of
IG/TR gene rearrangements within the total (rearranged)
BCP-ALL population is generally similar throughout the
BM compartment and between BM and PB. Apparently,
after their development at different BM sites in the body,
almost all IG/TR-defined clones within a BCP-ALL popu-
lation, even the small subclones, disseminate homoge-
neously via PB throughout the BM compartment. 
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